GoodRx (GDRX) 2024 Wells Fargo Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
2024 Wells Fargo Healthcare Conference summary
22 Jan, 2026Forward-looking statements and financial metrics
Session included forward-looking statements about plans, strategies, and financial performance, with reference to risk factors in recent filings.
Non-GAAP metrics may be referenced, reconciled in earnings releases and filings.
Cash pay deals and pharma partnerships
Pharma is increasingly targeting cash pay customers with direct-to-consumer pricing, especially for non-formulary drugs.
Recent deals with Sanofi, Dexcom, and Boehringer Ingelheim highlight growth in Manufacturer Solutions revenue.
The company leverages its large user base to implement and scale these programs.
Kroger partnership and direct contracting
Kroger rejoined the network in May under a direct contract, signaling the value of direct contracting amid pharmacy economic pressures.
Kroger's return was driven by reduced foot traffic and the need to regain customers.
Coupon views for Kroger are up, but full claim volume recovery will take several quarters.
Incremental Kroger volume is not included in current year guidance.
Direct contracting now covers a significant minority of relationships and is expected to grow.
Latest events from GoodRx
- Board recommends approval of all proposals at the virtual 2026 Annual Meeting.GDRX
Proxy filing29 Apr 2026 - Definitive additional proxy materials filed to inform shareholders of voting matters.GDRX
Proxy filing29 Apr 2026 - Sharpened strategy and robust growth in integrated savings and pharma solutions drive margin gains.GDRX
Morgan Stanley 22nd Annual Global Healthcare Conference5 Apr 2026 - Pharma Direct revenue surged 41% in 2025, driving growth despite headwinds in other segments.GDRX
Q4 202526 Feb 2026 - Q3 2025 saw strong manufacturer solutions growth and resilient financials amid industry headwinds.GDRX
Q3 20253 Feb 2026 - Q2 revenue up 6% to $200.6M, Adjusted EBITDA margin 32.6%, with cautious full-year outlook.GDRX
Q2 20242 Feb 2026 - Q3 2024 revenue up 8%, net income $4.0M, and margin expansion driven by pharma solutions.GDRX
Q3 202416 Jan 2026 - Direct contracting and manufacturer solutions drive growth and margin gains amid evolving PBM dynamics.GDRX
UBS Global Healthcare Conference 202414 Jan 2026 - New Surescripts partnership launches Script Corner for real-time prescription price transparency.GDRX
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026